Brexanolone caprilcerbate
A medication used for the treatment of postpartum depression
Brexanolone caprilcerbate is a medication primarily used in the treatment of postpartum depression (PPD). It is a novel formulation of the neuroactive steroid brexanolone, which is a synthetic form of the naturally occurring hormone allopregnanolone. This medication is administered intravenously and is specifically designed to address the unique hormonal changes that occur during the postpartum period.
Mechanism of Action[edit | edit source]
Brexanolone caprilcerbate acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) A receptor. GABA is the primary inhibitory neurotransmitter in the central nervous system, and its modulation is crucial for maintaining neurotransmission balance. By enhancing the effects of GABA, brexanolone caprilcerbate helps to stabilize mood and reduce symptoms of depression.
Pharmacokinetics[edit | edit source]
Brexanolone caprilcerbate is administered via a continuous intravenous infusion over a period of 60 hours. This method of administration ensures a steady concentration of the drug in the bloodstream, allowing for effective modulation of GABA_A receptors. The drug is metabolized in the liver and excreted primarily through the kidneys.
Clinical Use[edit | edit source]
Brexanolone caprilcerbate is specifically indicated for the treatment of moderate to severe postpartum depression in adult women. The treatment is typically administered in a controlled healthcare setting due to the need for continuous monitoring of the patient during the infusion process.
Side Effects[edit | edit source]
Common side effects of brexanolone caprilcerbate include dizziness, somnolence, and headache. Due to the potential for excessive sedation and loss of consciousness, patients are monitored closely during treatment. There is also a risk of hypoxia and hypotension, necessitating the availability of supportive care.
Regulatory Status[edit | edit source]
Brexanolone caprilcerbate was approved by the Food and Drug Administration (FDA) for the treatment of postpartum depression in 2019. It represents a significant advancement in the management of PPD, offering a rapid onset of action compared to traditional antidepressants.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
